Cervical Cancer Deaths Down Following HPV Vaccine Introduction
Reductions in cervical cancer incidence, mortality in the U.S. greater for those aged 15 to 24 years than those aged 25 to 29, 30 to 39 years
Reductions in cervical cancer incidence, mortality in the U.S. greater for those aged 15 to 24 years than those aged 25 to 29, 30 to 39 years
Fewer than expected cervical cancers, CIN3 cases seen among vaccinated cohorts after introduction of HPV immunization program in England
The approval was based on data from the phase 3 KEYNOTE-826 trial.
The approval was based on data from the phase 2 innovaTV 204 trial that evaluated Tivdak as monotherapy in 101 adult females with recurrent or metastatic cervical cancer.
Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.
The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.